Cite
HARVARD Citation
Domchek, S. et al. (2020). Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet oncology. 21 (9), pp. 1155-1164. [Online].